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Non-coding small RNA molecules, the microRNAs (miRNAs), contribute decisively to the epigenetic regu-
lation processes in cancer cells. Problematic pathogenic properties of cancer cells and the response of
cancers towards anticancer drugs are highly inﬂuenced by miRNAs. Both increased drug activity and for-
mation of tumor resistance are regulated bymiRNAs. Further to this, the survival and proliferation of cancer
cells and the formation ofmetastases is based on themodulated expression of certainmiRNAs. Inparticular,
drug-resistant cancer stem-like cells (CSCs) depend on the presence and absence of speciﬁc miRNAs.
Fortunately, several smallmolecule natural compoundswerediscovered that targetmiRNAs involved in the
modulation of tumor aggressiveness and drug resistance. This review gives an overview of the effects of a
selection of naturally occurring small molecules (alkaloids, organosulfur compounds, aliphatic carboxylic
acids and water-soluble vitamins) on miRNAs that are closely tangled with cancer diseases.
© 2016 The Author. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction maturemiRNAs via binding to the 30-untranslated region (30UTR) ofMicroRNAs (miRNAs) feature short and highly conserved non-
coding RNAs of 22e23 nucleotides and there are more than two
thousand miRNAs that regulate about one-third of all human genes
[1]. In fact, the regulation of important cellular processes such as
proliferation, apoptosis, and differentiation of cells involves miR-
NAs [2]. MiRNAs also feature valuable diagnostic and prognostic
factors because characteristic miRNA expression patterns were
identiﬁed in tumor tissues [3e7]. The survival of drug-resistant
cancer stem-like cells (CSCs) is regulated by special miRNAs as
well [8,9]. MiRNAs also play an essential part concerning the for-
mation of metastases due to regulation of epithelial-to-
mesenchymal transition (EMT) of cancer cells [10,11].
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6.09.001the mRNAs [12]. Single miRNAs can target various genes while
dysregulation of tumor suppressor or oncogenic miRNAs was
observed in many human cancer types [13,14]. Thus, miRNAs with
effects on carcinogenesis, cell proliferation and differentiation,
apoptosis, and on the formation of metastasis and drug resistance
feature valuable targets for the design of potent anticancer drugs
[15e17]. Next generation anticancer drugs should either inhibit the
activity of oncogenic miRNAs or promote the activity of tumor
suppressor miRNAs. A recent review published in this journal
before dealt with miRNA-modulating natural phenols and terpe-
noids and their effects on various tumors [18]. This review provides
an overview of further anticancer active natural products (alka-
loids, organosulfur and aliphatic carboxylic acid derivatives, water-
soluble vitamins) and their manifold and versatile interactions with
miRNAs involved in cancer diseases.2. Dietary compounds and natural products (alkaloids,
organosulfur compounds, aliphatic carboxylic acids and
water-soluble vitamins) with effects on miRNA expression and
activity
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modulatory dietary factors and natural products for improved cancer
rboxylic acids and water-soluble vitamins, Non-coding RNA Research
B. Biersack / Non-coding RNA Research xxx (2016) 1e132need to explore. In order to develop potent agents against deadly
diseases such as cancer, it is necessary to investigate the modes of
action of these dietary and natural products thoroughly. There are
very promising derivatives from the natural compound classes of
alkaloids, organosulfur compounds, aliphatic carboxylic acids and
water-soluble vitamins. Their multiple modes of action and their
manifold interactions with miRNAs represent the key issues of this
review manuscript.
2.1. Alkaloids
Alkaloids feature a rich compound class (ca. 12.000 alkaloids
were investigated as bioactive compounds) comprising small
molecule natural amines and N-heterocyclic natural products [19].
Several alkaloids have shown potent anticancer activity and some
of them (e.g., Vinca alkaloids, camptothecins) have already been
approved for chemotherapy of certain cancer and leukemia dis-
eases, while others (e.g., DIM, berberine, vitamin C) seem to be
valuable additives for chemotherapeutic regimens. The interactions
of anticancer active alkaloids subdivided into indole alkaloids on
the one hand, and quinoline, isoquinoline and quinolizidine alka-
loids on the other hand, are presented in this chapter.
2.1.1. Indole alkaloids
Indole-3-carbinol was detected in various Brassica vegetables
(e.g., broccoli, cabbage, cauliﬂower, sprouts) and its condensation
product 3,30-diindolylmethane (DIM) is generated after consump-
tion in the stomach under acidic conditions (Fig. 1) [20]. The more
stable compound DIM revealed distinct anticancer activities via
suppression of the PI3K-Akt-mTOR signaling pathway and via in-
hibition of epigenetic factors such as DNA-methyl transferases/
DNMTs (hypomethylation) and histone deacetylases (HDACs)
[21,22]. Several clinical trials of I3C and DIM have revealed that both
I3Ca and DIM were well tolerable and further trials with DIM in
prostate cancer patients, in patients with cervical dysplasia and as
preventive agent in healthy non-smokers are ongoing [23]. DIM
(more precisely, formulated DIM called BR-DIM with improved
bioavailability) increased the expression of tumor suppressing let-7
miRNAs associated with suppression of the let-7-target EZH2 (a
histone-lysine N-methyltransferase) and inhibition of prostate tu-
mor growth (LNCaP, C4-2B, PC-3) [24]. In pancreatic cancer cells
(Colo357, Panc-1), DIM induced miR-146a expression leading to
suppression of EGFR (epidermal growth factor receptor), IRAK-1
(interleukin 1 receptor-associated kinase 1), NF-kB (nuclear factor
kB) andMTA2 (metastasis-associated protein 2) and to inhibition of
cancer cell invasion [25]. DIM also upregulated let-7b/c/d/e and
miR-200b/c in gemcitabine-resistant pancreatic cancer cells (Mia-
PaCa-2) causing a reversal of the EMT (epithelial-to-mesenchymalN
H
OH
I3C
HN NH
DIM
Fig. 1. Structures of the indole alkaloids I3C and DIM.
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meobox 1), slug and vimentin and upregulation of E-cadherin [26].
In combination with Herceptin, DIM increased miR-200 expression
accompanied by FoxM1 suppression and induction of apoptosis in
HER-2 positive breast cancer cells (SKBR3, MDA-MB-468) [27]. DIM
also induced miR-34 expression in castrate-resistant prostate
cancer cells associated with inhibition of Notch-1 and androgen
receptor (AR) signaling and lowered the self-renewal potential of
prostate cancer cells [28]. In breast cancer models (T47D, MDA-MB-
231), DIM increased the expression of the miRNA cluster miR-212/
132 via activation of the aryl hydrocarbon receptor (Ahr) leading to
the suppression of the pro-metastatic protein Sox4 (SRY-related
HMG-box 4) both in vitro and in vivo, to reduced tumor growth and
to inhibition of metastasis formation [29].
Concerning oncogenic miRNAs (oncomiRs), I3C suppressedmiR-
21 expression in pancreatic cancer cells (Panc-1) leading to upre-
gulation of the miR-21 target PDCD4 (programmed cell death
protein 4) and enhanced gemcitabine-sensitivity of the I3C-treated
cancer cells [30]. In vinyl carbamate-induced lung cancer, I3C was
able to suppress the upregulated miRNAs miR-21, miR-31, miR-
130a, miR-146b, and miR-377 [31]. In addition, DIM down-
regulated miR-221 in pancreatic cancer cells (MiaPaCa-2, Pan377 c-
1) associated with upregulation of the miR-221 targets PTEN
(phosphatase and tensin homolog deleted on chromosome 10),
PUMA (p53 upregulated modulator of apoptosis), and the
CDK(cyclin-dependent kinase)-inhibitors p27 and p57 [32]. Inter-
estingly, DIM revealed inhibitory effects on bone metastasis for-
mation by prostate cancers via suppression of miR-92 [33].
Surprisingly, DIM enhanced the expression of miR-21 in breast
cancer cells leading to degradation of Cdc25A and cancer cell
growth inhibition [34]. Thus, in this special case miR-21 can also
function as a tumor suppressor. A list of miRNAs regulated by DIM
and I3C is shown in Table 1.
Tubulin-binding Vinca alkaloids (e.g., vinblastine, vincristine)
were ﬁrst isolated from the Madagascar periwinkle (Catharanthus
roseus) in the 1960's and feature complex indole alkaloids which
represent valuable and approved anticancer drugs for the treat-
ment of advanced cancer diseases (Fig. 2) [35]. The semi-synthetic
Vinca alkaloid vinorelbine (Fig. 2) revealed an improved toxicity
proﬁle compared with vinblastine and vincristine. Due to clinical
drawbacks such as emerging multidrug-resistance upon treatment
with Vinca alkaloids, the role of miRNAs for the induction of
resistance to Vinca alkaloids was investigated in various cancer
models. In breast cancer cells, miR-27a and miR-451 induced
expression of the ABC-transporter MDR1/Pgp, and suppression of
miR-27a andmiR-451was accompanied by increased accumulation
of vinblastine in cancer cells [36]. Similar results were observed
from MCF-7 breast cancer cells, where vinblastine suppressed the
expression of miR-27a, miR-27b, miR-324-3p, miR-328, miR-148a
and miR-451, while these miRNAs were not affected by vinblas-
tine in colon cancer cells (Caco-2) [37]. In particular, the down-
regulation of miR-27b, miR-148a, and miR-451 by vinblastine was
associated with increased expression of ABC-transporters such as
ABCB1 and ABCC1 leading to enhanced drug efﬂux from the cancer
cell [38]. MiR-34a expression enhanced the antiproliferative ac-
tivity of vincristine in retinoblastoma cells by suppression of
HMGB1 (high mobility group box 1) [38]. Vincristine-resistant he-
patocellular carcinoma (HCC) cells exhibited upregulated miRNAs
such as miR-27b, miR-181a, miR-146b-5p, miR-181d and miR-146a
[39]. In addition, vincristine-resistant laryngeal cancer cells (Hep-2/
v) exhibited increased expression of miR-210 and miR-923, while
ﬁve miRNAs were suppressed (miR-93, miR-93*, miR-424*, miR-
25*, miR-494) [40]. Overexpression of the oncogenic miR-125b in
Ewing sarcoma cells decreased the anticancer activity of vincristine
[41]. R-CHOP (rituximab, cyclophosphamide, adriamycin,modulatory dietary factors and natural products for improved cancer
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Fig. 2. Structures of the Vinca alkaloids and staurosporine.
Table 1
Regulation of microRNAs by DIM and I3C.
Compound Tumor suppressors (up-regulated) Oncogenes (down-regulated)
DIM let-7b/c/d/e [24,26], miR-21(!) [34], miR-34
[28], miR-146a [25], miR-200b/c [27], miR-212/132 cluster [29]
miR-92 [33], miR-221 [32]
I3C  miR-21 [31], miR-31 [31], miR-130a [31], miR-146b [31], miR-377 [31]
B. Biersack / Non-coding RNA Research xxx (2016) 1e13 3vincristine, prednisone) is clinically approved for the treatment of
diffuse large B-cell lymphoma (DLBCL) and DLBCL-patients with
high miR-224 levels (associated with low CD59 expression)
responded better to R-CHOP treatment (longer overall survival and
progression free survival) than patients with low miR-224 expres-
sion [42]. Key components of R-CHOP such as vincristine showed
increased anticancer activity in DLBCL cells overexpressing miR-
199a or miR-497, and expression of miR-199a and miR-497 led to
prolonged overall survival of DLBCL patients [43]. Inhibition of miR-
133a/b and miR-361-3p induced cell cycle arrest (S phase arrest)
and apoptosis (activation of caspase-3/7) and enhanced the anti-
proliferative effects of vinorelbine and of another tubulin target-
ing drug (paclitaxel) in H1993 non-small cell lung cancer cells
(¼NSCLC cells) signiﬁcantly [44]. In vinorelbine-resistant MDA-MB-
231/Nvb breast cancer cells, four miRNAs (miR-138-5p, miR-140-
3p, miR-210-3p and miR-3613-5p) were upregulated both in the
cancer cells and in the exosomes [45]. It is assumed that drug
resistance can be transmitted to other cancer cells via exosomes
loaded with oncogenic miRNAs. MAPK, mTOR, Wnt and TGF-b
signaling pathways contributed to vinorelbine-resistance in resis-
tant MDA-MB-231/Nvb breast cancer cells via dysregulated miRNA
expression [46]. Eleven miRNAs (miR-138-5p, miR-182-5p, miR-
18a-5p, miR-193b-3p, miR-199a-5p, miR-210-3p, miR-21-5p, miR-
378a-3p, miR-4262, miR-4725-5p, and miR-92b-3p) were upregu-
lated while 6 miRNAs were downregulated (let-7a-5p, miR-130a-
3p, miR-146a-5p, miR-221-3p, miR-23b-3p, and miR-4319) in
vinorelbine-resistant breast cancer cells [46]. Patients suffering
fromNSCLC treatedwith a combination of vinorelbine and cisplatinPlease cite this article in press as: B. Biersack, Non-coding RNA/microRNA-
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(2016), http://dx.doi.org/10.1016/j.ncrna.2016.09.001were examined for prognostic miRNA markers and the microRNAs
miR-149 and miR-375 were found predictive for response to the
combination treatment and progression free survival [47]. In
addition, four other miRNAs (miR-29c, miR-124, miR-200c, and
miR-424) were applied as a signature for overall survival of NSCLC
patients treated with cisplatin-vinorelbine [47].
The indole alkaloid staurosporine features a natural pan-kinase
inhibitor and the prototype for the design of more selective protein
kinase inhibitors approved for clinical application as anticancer
agents (Fig. 2) [48]. Staurosporine induced apoptosis in prolifer-
ating human cells and overexpression of miR-31 augmented the
apoptosis induction by staurosporine via downregulation of PKCε
and Bcl-2 in MCF10A breast epithelial cells [49]. In Wi38 ﬁbroblast
cells, staurosporine-induced apoptosis was mediated by functional
miR-34 in a p53-dependent way and suppression of miR-34
reduced apoptosis induction by staurosporine due to upregula-
tion of Bcl-2 [50]. In addition, apoptosis induction by staurosporine
was mediated by expression of miR-145 leading to inhibition of
DFF45 (DNA fragmentation factor-45) [51]. In contrast to that, miR-
125b expression suppressed apoptosis induction by staurosporine
via downregulation of pro-apoptotic Bmf and KLF13 in MPP (mul-
tipotent progenitor) cells and Jurkat T-cell leukemia cells [52].
Suppression of miR-24 potentiated the apoptosis induction by
staurosporine in prostate cancer cells via upregulation of pro-
apoptotic FAF1 (Fas associated factor 1) [53]. Table 2 shows a list
of miRNAs involved in sensitivity or resistance to indole alkaloids
such as Vinca alkaloids and staurosporine.
Anticancer agents that bind covalently to nucleotides likelymodulatory dietary factors and natural products for improved cancer
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Table 2
Inﬂuence of microRNAs on cellular sensitivity or resistance to Vinca alkaloids and staurosporine.
Compounds Sensitivity Resistance
Vinblastine  miR-27a [36,37], miR-27b [37], miR-148a [37], miR-324-3p [37],
miR-328 [37], miR-451 [36,37]
Vincristine miR-25* [40], miR-34a [38], miR-93 [40], miR-93* [40], miR-199a
[43], miR-224 [42], miR-424* [40], miR-494 [40], miR-497 [43]
miR-27b [39], miR-125b [41], miR-146a [39], miR-146b-5p [39],
miR-181a [39], miR-181d [39], miR-210 [40], miR-923 [40]
Vinorelbine let-7a-5p [46], miR-23b-3p [46], miR-130a-3p [46], miR-146a-5p
[46], miR-149 [47], miR-221-3p [46], miR-375 [47], miR-4319 [46]
miR-18a-5p [46], miR-21-5p, miR-92b-3p [46], miR-133a/b [44],
miR-138-5p [45,46], miR-140-3p [45], miR-182-5p [46], miR-193b-
3p [46], miR-199a-5p [46], miR-210-3p [45,46], miR-361-3p [44],
miR-378a-3p [46], miR-3613-5p [45], miR-4262 [46], miR-4725-5p
[46]
Staurosporine miR-31 [49], miR-34 [50], miR-145 [51] miR-24 [53], miR-125b [52]
B. Biersack / Non-coding RNA Research xxx (2016) 1e134modulate the expression and activity of oligonucleotides such as
non-coding RNAs and miRNAs as well. The indole alkaloid and
approved anticancer drug mitomycin C was initially isolated from
Streptomyces caspitosus and causes DNA damage via mono- and
bifunctional alkylations (formation of cross-links) (Fig. 3) [54,55].
Alkylation of nucleobases (guanine-N2) by mitomycin C requires
the activation of mitomycin C via enzymatic reduction (e.g., by DT-
diaphorase) of its quinone ring system [56]. In urothelial bladder
cancer (UBC) cells, miR-31 served as a tumor suppressor and
sensitized UBC cells to mitomycin C via direct suppression of ITGA5
(integrin a5) and inhibition of Akt and ERK signaling [57]. MiR-31
also increased the tumor growth inhibitory activity of mitomycin
C in vivo in UBC xenografts (T24) [57]. However, the nucleotide
binding properties of alkylating agents such as mitomycin C harbor
the danger of long-term genotoxicity and of inheritable aberration
of miRNA expression leading to new cancer diseases as side-effects
[58]. Indeed, treatment of HeLa cells with mitomycin C revealed
increased inherited expression of ﬁve oncogenic miRNAs (miR-19b-
3p, miR-21-3p, miR-30a-3p, miR-30e-3p, miR-182-5p) and inheri-
ted downregulation of nine tumor suppressor miRNAs (miR-23b-
3p, miR-29b-3p, miR-99a-5p, miR-99b-5p, miR-100-5p, miR-148a-
3p, miR-193a-3p, miR-340-5p, miR-365a-3p) [58].2.1.2. Quinoline, isoquinoline and quinolizidine alkaloids
The anticancer active quinoline alkaloid camptothecin (CPT) was
isolated from the Chinese tree Camptotheca acuminata [59]. CPTand
its water-soluble derivatives topotecan and irinotecan represent
important approved anticancer drugs for the treatment of various
hematological malignancies and solid tumor diseases (Fig. 4) [60].
CPT and its derivatives induce apoptosis by inhibition of topo-
isomerase 1 (Top1) and stabilization of the Top1-DNA cleavage
complex leading to toxic DNA damage [61]. The connection be-
tween CPT activity and miRNA expression was investigated. For
instance, downregulation of oncogenic miR-125b was observed in
apoptotic cancer cells upon treatment with CPT [62]. MiR-125b-Mitomycin C
N
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Fig. 3. Chemical structure of mitomycin C.
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(2016), http://dx.doi.org/10.1016/j.ncrna.2016.09.001mediated mitochondrial apoptotic pathways were induced by CPT
associated with increased expression of the pro-apoptotic factors
Bak1, Mcl1, and p53 [62]. In line with these ﬁndings, the ectopic
expression of miR-125b blocked apoptosis induction by CPT [62]. In
contrast to that, overexpression of the tumor suppressing miRNAs
miR-15a andmiR-16 sensitized HeLa cervical carcinoma cells to CPT
treatment and enhanced autophagy in HeLa cells via suppression of
Rictor, a component of the mTORC2 complex, followed by the in-
hibition of phosphorylation of mTORC1 and p70S6K [63]. CPT de-
rivatives modulated the response of glioma cells to hypoxia and the
connection between HIF-1 (hypoxia-inducible factor 1) and
microRNAs upon treatment with CPT was investigated [64,65].
Indeed, CPT upregulated the expression of miR-155 and miR-17-5p
leading to inhibitory effects on HIF-1a expression and activity in
hypoxic HeLa cancer cells [65]. In colorectal cancer stem cells, the
upregulation of miR-451 reduced resistance to the water-soluble
CPT derivative irinotecan associated with suppression of Wnt-
signaling and COX-2 (cyclooxygenase 2) expression as well as
downregulation of the ABC-transporter ABCB1 (which eliminates
intracellular irinotecan molecules) [66]. The activity of irinotecan
was increased by suppressed miR-21 expression in gastric cancer
and lowmiR-21 expression resulted into irinotecan-sensitivity [67].
The expression of the multidrug resistance mediating ABC trans-
porter ABCG2 is regulated by miR-519c and irinotecan-resistant
colorectal cancer showed low levels of miR-519c but high levels
of ABCG2 [68]. In HCC cells, overexpression of miR-23a induced
irinotecan-resistance via downregulation of topoisomerase 1
expression [69]. In patients suffering from metastatic colorectal
cancer, the appearance of single-nucleotide polymorphisms (SNPs)
in the miR-26a-1 gene and in the 50UTR of pre-miR-100 led to
prolonged overall survival and progression-free time when treated
with a combination of 5-FU (5-ﬂuorouracil) and irinotecan [70]. In
addition, the efﬁcacy of anti-EGFR therapy (cetuximab) in combi-
nation with irinotecan was distinctly enhanced in a group of KRAS-
mutated, chemotherapy-refractory colorectal cancer patients with
high let-7a levels accompanied by improved survival which paves
the way for new therapy options in these cases [71]. In addition,
high levels of miR-345 were correlated with resistance to irinote-
can plus cetuximab 3rd line treatment in colorectal cancer patients
and in non-KRAS mutant patient sub-groups [72]. Across the panel
of the NCI-60 cell lines, topotecan and irinotecan suppressed miR-
24 expression, while upregulation of miR-24 decreased Top1
sensitivity to Top1 poisons [73]. In breast cancer cells (MCF-7),
oncogenic miR-21 was involved in topotecan-resistance and
downregulation of miR-21 re-sensitized breast cancer cells to
topotecan [74]. In addition, the modulation of miRNAs associated
with drug resistance in 16 ovarian cancer cell lines upon treatment
with topotecan was investigated [75]. Three microRNAs (miR-34b,
miR-431, miR-518c-AS) were upregulated by topotecan treatment,
while miR-142-5p was downregulated by topotecan in drug resis-
tant ovarian cancer cells [75].modulatory dietary factors and natural products for improved cancer
rboxylic acids and water-soluble vitamins, Non-coding RNA Research
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Fig. 4. Chemical structures of camptothecin derivatives and trabectedin.
B. Biersack / Non-coding RNA Research xxx (2016) 1e13 5The natural compound trabectedin (Ecteinascidin 743, Yonde-
lis®) represents an alkylating tetrahydroisoquinoline alkaloid
initially isolated from the tunicate Ecteinascidia turbinata of the
Caribbean Sea, which is the host of the trabectedin-forming bac-
terial symbiont Endoecteinascidia frumentensis (Fig. 4) [76]. Tra-
bectedin exhibited strong cytotoxic activity against various tumors
and was approved for the therapy of soft tissue sarcoma and
ovarian cancer [76]. Trabectedin damages DNA by a unique mech-
anism, the trabectedin molecule binds to nitrogen-N2 of guanine
bases of the DNA minor groove which causes a bended DNA
molecule followed by interaction with DNA binding proteins of the
TC-NER (transcription-coupled nucleotide excision repair) DNA-
repair system leading to cell death in the end via formation of
double strand breaks in particular in HR(homologous
recombination)-deﬁcient cells [76]. In addition, trabectedin
inhibited the transcription activity of FUS-CHOP in sensitive myx-
oid liposarcoma (MLS) [77]. Facing the inﬂuence of trabectedin on
transcription, D'Incalci and coworkers investigated the effects of
trabectedin on miRNA expression in MLS cells (402-91 sensitive
and 402-91/ET trabectedin-resistant MLS cells) [78]. In the
trabectedin-resistant cells, the tumor suppressor let-7e was sup-
pressed (three-fold) and oncogenic miR-21 was upregulated (two-
fold) when compared with the sensitive MLS cells which was
consequently accompanied by the upregulation of let-7e targets
(CCDN1, SEMA4C, E2F5) and suppression of miR-21 targets (PDCD4)
in the resistant cells [78]. In addition, the tumor suppressors miR-
192, miR-130a and miR-98 were downregulated in 402-91/ETTable 3
Inﬂuence of microRNAs on cellular sensitivity or resistance to camptothecin derivatives
Compounds Sensitivity
Camptothecin miR-15a [63], miR-16 [63]
Irinotecan let-7a [71], miR-451 [66], miR-519c [68]
Topotecan miR-124-5p [75]
Trabectedin let-7e [78], miR-98 [78], miR-130a [78], miR-192 [78]
Please cite this article in press as: B. Biersack, Non-coding RNA/microRNA-
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(2016), http://dx.doi.org/10.1016/j.ncrna.2016.09.001cells, while oncogenic miR-7 was induced. The genes of the miRNAs
miR-7, miR-21 and miR-130a harbor CHOP-binding motifs in their
promoters and, thus, are probably modulated by trabectedin in a
FUS-CHOP dependent way [78]. A list of miRNAs involved in drug
resistance or sensitivity to camptothecins and trabectedin is shown
in Table 3.
The isoquinoline alkaloid berberine features a quaternary
cationic quinolizinium derivative found in various medicinal plants
such as Berberis aristata, Coptis chinensis and C. japonica, Phellon-
dendron amurense and P. chinense (Fig. 5) [79]. Berberine induces
cytotoxic effects in cancer cells by interaction with DNA leading to
double-strand breaks, telomerase inhibition by triplex and G-
quadruplex formation and stabilization of the topoisomerase-DNA
“cleavable complex” [79]. In multiple myeloma cells (U266),
berberine induced apoptosis via suppression of oncogenic miR-21
and anti-apoptotic Bcl-2, and via inhibition of NF-kB translocation
[80]. Berberine-mediated suppression of miR-21 in multiple
myeloma cells was associated with upregulation of PDCD4
expression [81]. It is assumed that berberine inhibits miR-21
expression via suppression of IL6 (interleukin 6) and STAT3
(signal transducer and activator of transcription) [81]. In addition,
berberine sensitized ovarian cancer cells (SKOV3) to cisplatin
treatment via suppression of miR-21 and increased expression of
the tumor suppressor PDCD4 [82].
During the processing of the precursor miRNA hairpin a miRNA
duplex is formed that consists of a guide strand (termed miRNA)
that forms the miRISC complex upon binding to Argonaute (AGO),and to trabectedin.
Resistance
miR-125b [62]
miR-21 [67], miR-23a [69], miR-24 [73], miR-345 [72]
miR-21 [74], miR-24 [73], miR-34b [75], miR-431 [75], miR-518c-AS [75]
miR-7 [78], miR-21 [78]
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to be non-functional in most cases and to be degraded soon.
However, the passenger strand leading to miR-21* (¼miR-21-3p)
plays an important role for the regulation of cell growth as well. In
hepatocellular carcinoma cells (HepG2), berberine increased the
levels of miR-21-3p associated with tumor growth inhibition and
apoptosis induction [83]. It was shown that miR-21-3p acted as a
tumor suppressor in the hepatoma cells and directly inhibited the
expression of the methionine adenosyltransferases MAT2A and
MAT2B accompanied by increased SAM (S-adenosyl-methionine)
levels as a mechanism of the anti-hepatoma activity of miR-21-3p
and berberine [83]. Berberine also signiﬁcantly suppressed the
miRNA clusters miR-99a~125b, miR-17e92 and miR-106e25 in
multiple myeloma cells [84]. In particular, downregulation of the
oncogenic miR-99a~125b cluster by berberine (mediated by mod-
ulation of p53, Erb and MAPK signaling pathways) induced
apoptosis and cell cycle arrest in the G2-phase in multiple myeloma
cells [84].
Palmatine features another isoquinoline alkaloid of the roots of
Coptis japonica whose chemical structure is closely related to
berberine (Fig. 5) [85]. Palmatine revealed anticancer activity
against prostate cancer cells by inhibition of NF-kB [86]. In breast
cancer cells (MCF-7), the expression of the tumor suppressor miR-
200c was increased after treatment with palmatine chloride lead-
ing to ZEB1 inhibition and E-cadherin upregulation [87]. In addi-
tion, palmatine chloride induced the expression of the tumor
suppressors miR-34a and miR-141 in MCF-7 breast cancer cells
[87].
The quinolizidine alkaloid matrine was isolated from Sophora
ﬂavescens and exhibited strong anticancer activity (Fig. 5) [88]. In
breast cancer cells, matrine induced cell cycle arrest and apoptosisTable 4
Regulation of microRNAs by isoquinoline and quinolizidine alkaloids.
Compounds Tumor suppressors (up-regulated) Oncogenes (d
Berberine miR-21-3p [83] miR-21 [80],
Palmatine chloride miR-34a [87], miR-141 [87],
miR-200c [87]
e
Matrine e let-7b-5p [89
19b-3p [89],
miR-27a-3p [
5p [89], miR-
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as well as upregulation of PTEN (phosphatase and tensin homolog)
[88]. Matrine also modulated miRNA levels in gastric cancer cells
and suppressed the expression of 20 oncomirs overexpressed in
gastric cancer cells including let-7b-5p, miR-10a-5p, miR-15b-5p,
miR18a-5p, miR-19a-3p, miR-19b-3p, miR-20b-5p, mir-21-5p,
miR-23a-3p, miR-26b-5p, miR-27a-3p, miR-27b-3p, miR-32-5p,
miR-34a-5p, miR-98, miR-106b-5p, miR-181a-5p, miR-183-5p and
miR-338-3p [89]. A list of miRNAs regulated by isoquinoline and
quinolizidine alkaloids is shown in Table 4.
2.2. Organosulfur-based natural products
Organosulfur-based natural products include sulﬁdes and iso-
thiocyanates that occur in Allium species (garlic) and in cruciferous
vegetables (e.g., broccoli, watercress) and revealed distinct epige-
netic effects in cancer cells [90]. The natural garlic disulﬁde diallyl
disulﬁde (DADS, Fig. 6) is usually metabolized to S-allylmercapto-
cysteine (SAMC) and to allyl mercaptan (AM) and exhibited tumor
cell growth inhibition, apoptosis induction as well as inhibition of
metastasis formation and angiogenesis [91,92]. DADS and to a
greater extend its metabolite AM strongly inhibited histone
deacetylases (HDACs) [93,94]. In gastric cancer cells (MGC-803),
DADS inhibited cell growth and induced apoptosis via induction of
miR-200b and miR-22 expression leading to inhibition of Wnt-1
signaling [95]. In addition, the expression of the tumor suppres-
sors miR-200b and miR-22 enhanced the growth inhibitory activity
and the anticancer effects of DADS both in vitro and in vivo [95].
DADS also inhibited breast cancer proliferation and metastasis
formation by upregulation of the tumor suppressor miR-34a asso-
ciated with blocked Src/Ras/ERK signaling (with the Src gene as aown-regulated)
miR-99a~125b cluster [84], miR-17~92 cluster [84], miR-106~25 cluster [84]
], miR-10a-5p [89], miR-15b-5p [89], miR-18a-5p [89], miR-19a-3p [89], miR-
miR-20b-5p [89], miR-21 [88], mir-21-5p [89], miR-23a-3p [89], miR-26b-5p [89],
89], miR-27b-3p [89], miR-32-5p [89], miR-34a-5p [89], miR-98 [89], miR-106b-
181a-5p [89], miR-183-5p [89], miR-338-3p [89]
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DADS-mediated induction of miR-34a suppressed the PI3K/Akt
signaling pathway and successfully blocked cancer cell invasion
while apoptosis was strongly induced in DADS-treated cells [97].
Sulforaphane (SFN) features an isothiocyanate derivative of
cruciferous vegetables, which inhibits carcinogenesis as well as
tumor growth in vivo (Fig. 6) [98]. In the plants, isothiocyanates
with strong effects on various epigenetic mechanisms occur as
more stable glucosinolate prodrugs that release the reactive iso-
thiocyanate agent upon consumption catalyzed by the enzyme
myrosinase [99]. SFN itself induced cell cycle arrest via p21 acti-
vation and inhibited HDAC enzymes such as HDAC6 [90]. In bladder
cancer cells (T24), SFN induced the expression of the tumor sup-
pressor miR-200c associated with blocked EMT and inhibition of
metastasis formation [100]. Similar effects (miR-200c upregulation,
suppression of cancer stemness) were observed from oral squa-
mous cell carcinomas after treatment with SFN [101]. In addition,
miR-140was upregulated by SFN in breast cancer cells (MCF10DCIS,
and MDA-MB-231) leading to the suppression of SOX9 and alde-
hyde dehydrogenase 1 (ALDH1) [102]. The combination of SFN with
green tea catechins (GTCs) was much more anticancer active
against advanced pancreatic cancer than GTCs alone because of the
SFN-mediated increased expression of the tumor suppressor let-7a
leading to K-Ras inhibition [103]. In non-malignant colon epithelial
cells (NCM460, NCM356), SFN suppressed three miRNAs (miR-633,
miR-155, miR-106a*) while 15miRNAs (miR-372, miR-342-3p, miR-
486-5p, miR-9, miR-9*, miR-145, miR-146a, miR-629, miR-505,
miR-758, miR-30*, miR-27b*, miR-135*, miR-27b, miR-23b) were
upregulated by SFN which was associated with a reduced risk of
colon cancer development [104].
The closely related isothiocyanate phenethylisothiocyanate
(PEITC) from watercress exhibited enhanced histone acetylationTable 5
Regulation of microRNAs by natural organosulfur derivatives.
Compounds Tumor suppressors (up-regulated)
Diallyl disulﬁde miR-22 [95], miR-34a [96,97], miR-200b [95]
Sulforaphane let-7a [103], miR-9 [104], miR-9* [104], miR-23b [104], miR-27
miR-30* [104], miR-135* [104], miR-140 [102], miR-145 [104]
200c [100,101], miR-342-3p [104], miR-372 [104], miR-486-5
miR-629 [104], miR-758 [104]
PEITC let-7a [107], let-7c [107], miR-26a [107], miR-123-prec [107],
146-prec [107], miR-192 [107], miR-222-prec [107]
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Indeed, PEITC suppressed the oncogenic high-risk factormiR-141 in
prostate cancer cells (LNCaP) leading to increased expression of the
miR-141-target Shp (small heterodimer partner protein, a small
orphan receptor and corepressor) and suppressed androgen re-
ceptor (AR) signaling [106]. In order to examine the chemo-
preventive effects of PEITC, rats exposed to cigarette smoke were
treated with PEITC and a strong reversal of smoke-induced miRNA
suppression was observed in the lungs of the PEITC-treated rats.
These PEITC-induced miRNAs include miR-125b (stress response),
miR-26a (TGF-b expression), miR-146-prec (NF-kB activation), let-
7a and let-7c (Ras activation, cell proliferation and angiogenesis),
miR-192 (Ras activation), miR-222-prec and miR-123-prec (cell
proliferation and angiogenesis) [107]. It is assumed that PEITC is
able to modulate carcinogen metabolism leading to enhanced
inactivation and excretion of cigarette/tobacco smoke carcinogens
[107]. A list of miRNAs regulated by dietary organosulfur com-
pounds is given in Table 5.2.3. Natural aliphatic carboxylates
The simple aliphatic short-chain carboxylic acid butyric acid,
which was initially isolated from glycerol esters of butter, and its
sodium salt, sodium butyrate (NaB), were identiﬁed as non-
competitive pan-HDAC inhibitors (inhibition of class I and II
HDAC enzymes) with modulatory effects on microRNA expression
(Fig. 7) [108,109]. In colorectal cancer cells (HCT-116), high doses of
NaB (1e2 mM) downregulated the oncogenic clusters miR-17-92,
miR-106a-363 and miR-106b-25 as well as miR-34a, miR-222-5p,
miR-7, miR-221, miR-886, let-7b-3p, and miR-196b leading to p21
induction [110]. Several miRNAs were upregulated in colorectal
cancer cells upon treatment with NaB (miR-96, miR-183, miR-487b,
miR-381, miR-300, miR-215, miR-194, miR-874, miR-602, miR-95,
miR-320b, miR-492, miR-583, miR-184, miR-202, miR-1908, miR-
637, miR-424) [110]. NaB also downregulated the oncogenes miR-
135a and miR-106b in colon adenoma cells accompanied by upre-
gulation of p21 [111]. The tumor suppressorsmiR-15a andmiR-16-1
were upregulated by NaB in lung cancer cells (A549, H1299) [112].
In addition, the expression of miR-101, miR-143 and miR-145 was
induced by NaB in Burkitt's lymphoma cells (Raji) associated with
suppression of PI3K/Akt signaling and inhibition of tumor cell
growth [113]. In combination with VP-16, NaB suppressed
methylation of the p16INK4a promoter in Burkitt's lymphoma cells
[113]. NaB also induced miR-125a-5p expression in breast cancer
stem cells leading to increased apoptosis of breast cancer cells
[114]. In breast cancer cells (MDA-MB-231, MCF-7), NaB induced
cellular senescence via increased expression of miR-31 leading to
suppression of BMI1 [115]. Because of the low bioavailability of NaB,
NaB prodrugs such as AN-9 (Pivanex, pivaloyloxymethyl butyrate)
and tributyrin (tributyryl glyceride) were developed which showed
improved biological activities and pharmacokinetics [116,117].
The natural hydroxamic acid trichostatin A (TSA) represents an
antifungal antibiotic able to inhibit HDACs of the classes I and IIOncogenes (down-regulated)
e
b [104], miR-27b* [104],
, miR-146a [104], miR-
p [104], miR-505 [104],
miR-106a* [104], miR-155 [104], miR-633 [104]
miR-125b [107], miR- miR-141 [106]
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catalytic zinc ion of the active site of class I and class II HDAC en-
zymes leading to HDAC inhibition and hyperacetylation of histones
and of other HDAC targets in the TSA-treated cells [119]. TSA
reduced the expression of the oncogenic miR-106b-93-25 cluster
via MYC downregulation in endometrial cancer cells [120]. On the
other hand, TSA induced the expression of the tumor suppressor
miR-7 leading to EGFR suppression in triple-negative breast cancer
cells [121]. TSA-mediated upregulation of miR-125a-5p led to
enhanced apoptosis induction in breast cancer cells [122]. The
miRNA proﬁle of apoptosis-resistant breast cancer cells was
modiﬁed by TSA, i.e., the oncomirs miR-500 and miR-645 were
downregulated by TSA, and the tumor suppressors miR-1, miR-22,
miR-139, miR-143, miR-144, miR-153, miR-191*, miR-194, miR-
202*, miR-215, miR-335, miR-486 and miR-559 were upregulated
by TSA [123]. Oncogenic miR-155 was also upregulated by TSA-
treated breast cancer cells and combination of TSA with miR-155
targeting agents might improve the outcome of TSA-based thera-
pies [123]. In lung cancer cells, the levels of the tumor suppressors
miR-15a, miR-16-1, and miR-373 were increased after treatment
with TSA [124,125]. MiR-15a and miR-16-1 were also induced by
TSA in mantle cell lymphoma cells [126]. In liver cancer cells, miR-
129, miR-182-3p and miR-449 were upregulated by TSA, as well as
miR-129-5p in thyroid cancer cells and miR-375 in tongue cancer
cells [127e129]. In addition, the overexpression of the microRNAs
miR-30d, miR-181a and miR-199a-5p enhanced the anticancer ac-
tivity of TSA via suppression of the ER-chaperone GRP78 (glucose-
regulated protein) [130]. Colon cancer cells treated with TSA
showed increased levels of the tumor suppressor miR-449a/b
leading to inhibition of Fra-1 and of tumor cell growth and
migration [131]. In combinationwith the antimetabolite 5-aza-CdR,
TSA increased the expression of miR-29b, miR-30b and miR-31
[132]. In gastric cancer cells, TSA plus 5-aza-20-deoxycytidine
increased the expression of the tumor suppressor miR-10b leading
to tumor growth inhibition, reduced migration and invasion, and
enhanced apoptosis induction [133]. Similarly, the tumor sup-
pressor miR-219-2-3p was induced by TSA and 5-aza-20-deoxy-
cytidine in gastric cancer cells associated with suppression of p-
ERK1/2 [134]. In HCC cells, TSA plus 5-aza-20-deoxycytidine
increased the expression of miR-362-3p leading to suppression of
the cell cycle regulator Tob2 and to reduced tumor cell proliferation
and suppressed anchorage-independent growth [135]. In addition,
combination of TSA with 5-azaC enhanced tumor suppressor miR-
1-1 expression while combination of TSA with the DNMT inhibitor
zebularine induced miR-26b and let-7a expression [136e138].Please cite this article in press as: B. Biersack, Non-coding RNA/microRNA-
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(2016), http://dx.doi.org/10.1016/j.ncrna.2016.09.001Polyunsaturated fatty acids (PUFAs), in particular, n-3 PUFAs
such as docosahexaenoic acid (DHA, Fig. 7) and eicosapentaenoic
acid (EPA) feature signiﬁcant constituents of ﬁsh oil and revealed
distinct tumor suppressive effects, for instance, enhanced protec-
tion against colon tumorigenesis [139e142]. Rats fed with ﬁsh oil
rich in n-3 PUFAs revealed reduced carcinogenic effects of azoxy-
methane (AOM) in rat colons by upregulation of let-7d, miR-15b,
miR-107, miR-191, and miR-324-5p [143]. PUFAs such as DHA and
g-linolenic acid induced apoptosis in glioma cells by speciﬁc
downregulation of miR-143 while miR-20b was upregulated [144].
DHA distinctly increased the levels of tumor suppressing (let-7a)
and anti-angiogenic miRNAs (miR-21, miR-23b, miR-27b, miR-
320b) in the exosomes of breast cancer cells (MCF-7, MDA-MB-
231) while non-malignant breast cells exhibited no differences
[145]. Increased expression of miR-23b and miR-320b down-
regulated the expression of pro-angiogenic targets (PLAU, AMOTL1,
NRP1, ETS2) and contributed to the anti-angiogenic activity of DHA
[145]. Another study reported the suppression of the oncomir miR-
21 by DHA in breast cancer cells (MCF-7, MDA-MB-231) leading to
increased expression of PTEN and reduction of CSF-1 [146]. Mice
injected with HT-29 colon cancer showed reduced tumor growth
when fed with a walnut diet leading to increased levels of n-3
PUFAs such as DHA and EPA in themice [147]. The anticancer effects
of thewalnut diet weremediated by suppression of miR-467c, miR-
1903, andmiR-3068, and overexpression of miR-297* [147]. A list of
miRNAs regulated by aliphatic carboxylic acids is given in Table 6.
2.4. Water-soluble vitamins
Folic acid (FA, vitamin B9) is a natural vitamin occurring in
grains, fruits and vegetables and plays an important role concern-
ing DNA biosynthesis, DNA repair and DNA methylation (Fig. 8)
[148]. FA also modulated miRNAs involved in the development of
different cancer types. Rats fed with a folate-deﬁcient diet pro-
duced HCC after one year associated with upregulation of let-7a,
miR-21, miR-23, miR-130, miR-190, and miR-17-92 as well as sup-
pression of miR-122 in the developed hepatomas [149]. FA con-
sumption was accompanied by upregulation of miR-122 leading to
efﬁcient blocking of liver tumorigenesis [149,150]. In addition,
increased expression of miR-222 was observed from lympho-
blastoid cells devoid of FA supplement [151]. FAwas also applied for
certain “theranostic” purposes involvingmiRNAs since FA receptors
are often overexpressed on the cell surface of cancer cells. A
nanoprobe consisting of a gold nanoparticle modiﬁed with a ﬂuo-
rescein isothiocyanate (FITC)-labelled molecular beacon (MB thatmodulatory dietary factors and natural products for improved cancer
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Table 6
Regulation of microRNAs by natural aliphatic carboxylic acids.
Compounds Tumor suppressors (up-regulated) Oncogenes (down-regulated)
NaB miR-15a [112], miR-16-1 [112], miR-31 [115], miR-95 [110],
miR-96 [110], miR-101 [113], miR-125a-5p [114], miR-143
[113], miR-145 [113], miR-183 [110], miR-184 [110], miR-202
[110], miR-487b [110], miR-194 [110], miR-215 [110], miR-300
[110], miR-320b [110], miR-381 [110], miR-424 [110], miR-492
[110], miR-583 [110], miR-602 [110], miR-637 [110,], miR-874
[110], miR-1908 [110]
miR-17-92 cluster [110], miR-106a-363 cluster [110], miR-
106b-25 cluster [110], let-7b-3p [110], miR-7 [110], miR-34a
[110], miR-106b [111], miR-135a [110], miR-196b [110], miR-
221 [110], miR-222-5p [110], miR-886 [110]
TSA miR-1 [123], miR-7 [121], miR-15a [124-126], miR-16-1 [124-
126], miR-22 [123], miR-125a-5p [122], miR-129 [127,128],
miR-139 [123], miR-143 [123], miR-144 [123], miR-153 [123],
miR-182-3p [127], miR-191* [123], miR-194 [123], miR-202*
[123], miR-215 [123], miR-335 [123], miR-373 [124,125], miR-
375 [129], miR-449a/b [127,131], miR-486 [123], miR-559
[123]
miR-106b-93-25 cluster [120], miR-500 [123], miR-645 [123]
TSA þ antimetabolites miR-1-1 [136,137], miR-10b [133], miR-29b [132], miR-30b
[132], miR-31 [132], miR-219-2-3p [134], miR-362-3p [135]
e
TSA þ zebularine let-7a [138], miR-26b [138] e
n-3 PUFAs let-7a [145], let-7d [143], miR-15b [143], miR-20b [144], miR-
21 (anti-angiogenic) [145], miR-23b [145], miR-27b [145], miR-
107 [143], miR-191 [143], miR-297* [147], miR-324-5p [143],
miR-320b [145]
miR-21 [146], miR-143 [144], miR-467c [147], miR-1903 [147],
miR-3068 [147]
B. Biersack / Non-coding RNA Research xxx (2016) 1e13 9binds to miR-21) and PEGylated FA was prepared which docked to
cancer cells via the FA receptor [152]. Inside the cell, miR-21 bound
to the MBs of the nanoprobes induced a ﬂuorescence signal which
determined the miR-21 level within the cancer cells. Subsequent
irradiation with NIR (near infrared) light caused apoptosis via
photothermal effects of the gold nanoparticle which enhanced the
ﬂuorescence signal since remaining unbound MBs were unwinded
at higher temperatures [152]. Similarly, gold nanocages modiﬁedTable 7
Regulation of microRNAs by water-soluble vitamins.
Compounds Tumor suppressors (up-regulated)
Folic acid miR-122 [149,150]
Vitamin C miR-125b-2 [170], miR-134 [170], miR-135a [170], miR-345
[170], miR-375 [170], miR-422a [170], miR-490-5p [170], m
516a-3p [170], miR-596 [170], miR-630 [170], miR-663 [17
miR-708 [170], miR-1228 [170], miR-1915 [170]
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(2016), http://dx.doi.org/10.1016/j.ncrna.2016.09.001with PEGylated FA were able to bind and to deliver anti-miR-181b
molecules into HCC cells and the combined effects of the nanop-
robes comprising photothermal therapy andmiR-181b suppression
distinctly reduced tumor growth both in vitro and in vivo after NIR
irradiation [153].
Vitamin C (ascorbic acid) features a natural tetronic acid with
potent antioxidant properties and occurs in many easily available
fruits and vegetables (Fig. 8). Already Cameron and Campbell had
discovered the potent anticancer properties of vitamin C and an
initial clinical trial with terminal cancer patients who received a
combination of vitamin C infusions (10 g/day, i.v. for 10 days) and
oral vitamin C (10 g/day, 10 days) exhibited distinctly longer me-
dium survival in the vitamin C group (210 days) when compared
with untreated patients (50 days) [154,155]. A clinical study of the
Mayo Clinic used only oral vitamin C and, thus, could not reproduce
the promising results of Cameron and coworkers which underlines
the high importance of intravenous application of vitamin C in
order to reach sufﬁcient blood plasm concentrations of vitamin C
(up to 5.5 mmol/L after 10 g vitamin C, i.v.; up to 13.5 mmol/L after
50 g vitamin C, i.v.) [156e158]. Several newer cancer case studies
and trials that applied high-dose vitamin C infusions reported of
signiﬁcant tumor remission and reduced side-effects when com-
bined with chemotherapeutic agents (e.g., paclitaxel) [159e164]. A
phase I clinical trial of the combination of vitamin C and gemcita-
bine in metastatic pancreatic cancer patients (PACMAN study)
revealed a mean survival time of 13 months, which was more than
twice of the mean survival time of patients treated only with
gemcitabine (5.65 months) [164,165]. The mode of action of
vitamin C comprises the production of toxic H2O2 molecules that
kill the cancer cells in a selective way [158,166]. Resistance to
vitamin C was mediated by hypoxic conditions and HIF-1aOncogenes (down-regulated)
let-7a [149], miR-21 [149], miR-23 [149], miR-130 [149], miR-
190 [149], miR-17-92 [149], miR-222 [151]
iR-
0],
miR-93 [168], miR-153 [169]
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microRNAs were investigated as well. In breast tissues, vitamin C
inhibited carcinogenesis via suppression of oncogenic miR-93
associated with increased NRF2 (nuclear factor erythroid 2-
related factor 2) expression [168]. Similarly, in a more recent
study vitamin C inhibited breast carcinogenesis by suppression of
oncogenic miR-153 leading likewise to upregulation of NRF2 [169].
In melanoma cells, vitamin C increased the expression of 14 tumor
suppressing and EMT reversing miRNAs (miR-596, miR-630, miR-
422a, miR-490-5p, miR-375, miR-708, miR-345, miR-125b-2, miR-
516a-3p, miR-135a, miR-1228, miR-1915, miR-134, miR-663) [170].
The expression of miR-596, miR-630, miR-490, miR-375 and miR-
708 prolonged the overall survival of cancer patients when
compared with patient groups exhibiting only low expression of
these miRNAs [170]. A list of miRNAs regulated by water-soluble
vitamins is given in Table 7.
3. Conclusions
The expression of microRNAs involved in cancer-related pro-
cesses such as cell death, cell differentiation and proliferation,
angiogenesis and metastasis formation was modulated by several
natural and dietary compounds of known anticancer activity. The
effects of natural drugs selected from the classes of alkaloids,
organosulfur compounds, aliphatic carboxylic acids and water-
soluble vitamins on microRNAs contribute to their sound anti-
cancer activities. Low toxicity and reduced side-effects were
already observed from animal studies and clinical trials for several
of these natural compounds (e.g., DIM, vitamin C, etc.) that add
signiﬁcantly to conventional cancer therapies in consequence. In
addition, the activity of approved alkaloid anticancer agents such as
Vinca alkaloids and camptothecin and its derivatives was regulated
and strongly inﬂuenced by various tumor suppressor and onco-
genic miRNAs. In order to improve currently applied anticancer
therapies, a thorough knowledge of the regulation of relevant
miRNAs by small molecule natural products and dietary factors is
crucial. The therapeutic modulation of miRNAs harbors outstanding
prospects for anticancer patients such as better prognosis,
improved quality of life, and prevention of drug resistance.
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